Background Infantile epileptic spasms syndrome (IESS) is a rare but severe condition affecting children early and is usually secondary to an identifiable brain disorder. It is related to psychomotor deterioration in childhood and epilepsy in adult life. Treatment is challenging as infantile spasms may not respond to most antiseizure medication, and relapse is frequent. Objective To evaluate the literature regarding treatment of IESS and provide a practical guidance to a healthcare system with limited resources. Methods An expert committee from the Brazilian Society of Child Neurology reviewed and discussed relevant scientific evidence in the treatment of IESS regarding the drugs available in Brazil. Results Oral prednisolone and vigabatrin are the most common drugs used as first-line therapy; they are efficient and affordable therapy as both are available in the Brazilian unified health system (SUS, in the Portuguese acronym). Intramuscular adrenocorticotropic hormone (ACTH) presents similar efficacy as oral prednisolone but has a higher cost and is not available in Brazil. Other antiseizure medications such as topiramate, levetiracetam, or benzodiazepines have limited response and are prescribed as adjuvant therapy. If the health service has nutritionists, a ketogenic diet should be implemented for those not responding to hormonal and vigabatrin treatment. Epilepsy surgery is mainly indicated for patients with focal lesions that do not respond to pharmacological therapy. Conclusion Early treatment of IESS with efficient drugs is feasible in our country. Using standard protocols increases the odds of achieving complete cessation in a shorter time and decreases relapse.
This article aims to expand the understanding of how it is possible to alleviate suffering and enable a dignified life trajectory for patients with progressive neurological diseases or with severe and permanent neurological impairment. The four most common disease trajectories described for people with chronic and progressive disease used to advance care planning, Brazilian normative ethical resolutions, evidence-based benefits of palliative care (PC), as well as particularities of PC in neurology, such as neurological symptom control, caring for existential and psychological suffering, care provider’s needs and particularities of pediatric neurologic PC are reviewed.
Somatic neurological complications are an underexplored component of post-acute sequelae of SARS-CoV-2 infection. We evaluated long-term somatic neurological symptoms, examination findings, and suspected diagnoses among adults hospitalized for COVID-19. A total of 708 survivors were assessed 6–11 months after discharge using a structured three-step neurological evaluation based on the World Health Organization Protocol for Epidemiologic Studies of Neurologic Disorders : an adapted symptom questionnaire, a brief standardized neurological examination, and a full neurological consult. Muscle weakness, gait impairment, and paresthesias remained the most frequent symptoms at follow-up. Longer hospital stay predicted all three symptoms, and diabetes was associated with both gait impairment and paresthesias. Common examination findings included monoparesis, hemiparesis, and gradient-pattern sensory loss. Clinically suspected diagnoses included neuromuscular disease in 26%, cerebrovascular disease in 10%, and epilepsy in only 2.7% of cases. Logistic regression linked neuromuscular disease to paresthesias and tandem-walk failure, cerebrovascular disease to facial paralysis, and epilepsy to loss-of-contact episodes. A simplified screening model derived through best-subsets selection identified five informative items from the WHO protocol: paresthesias, facial paralysis, tandem walk, index–nose test, and loss-of-contact episodes. These findings indicate that somatic neurological abnormalities remain frequent months after severe COVID-19 and that a brief bedside subset may support efficient post-COVID neurological triage.